Sign in
4

Changes in Ownership

Allogene Therapeutics, Inc. Filed Acc 0001209191-19-019762

Chief Financial Officer acquired 49,400 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
SCHMIDT ERIC THOMAS Chief Financial Officer 2019-03-13 Grant or award +49,400 49,400 D: show line 1 in the form

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
SCHMIDT ERIC THOMAS Chief Financial Officer 2019-03-13 Grant or award · Employee Stock Option (Right to Buy) +83,500 83,500 D: show line 2 in the form
Loading xslF345X03/doc4.xml…